A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 17, 2012, Pages 2433-2442

  Derosa, Giuseppe ^a   Carbone, Anna ^b   D'angelo, Angela ^a   Querci, Fabrizio ^c   Fogari, Elena ^a   Cicero, Arrigo FG ^d   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Hospital Center of Diabetes   (Italy)

^c Alzano Lombardo   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chemerin; Metformin; Retinol binding protein 4; Sitagliptin; Visfatin

Indexed keywords

C PEPTIDE; CHEMERIN; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLACEBO; PROINSULIN; RETINOL BINDING PROTEIN 4; SITAGLIPTIN;

ADULT; BODY MASS; CELL FUNCTION; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; VOMITING;

AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; TRIAZOLES;

EID: 84869798707     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.730519     Document Type: Review

References (31)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
2. Asadollahi K, Beeching N, Gill G. Hyperglycaemia and mortality. J R Soc Med 2007;100:503-7
3. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35:S11-63
4. Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012;14:350-64
5. Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, beta-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2012; doi: 10.1016/j.diabres.2012.05.022
6. Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95
7. Ryden L, Standl E, Bartnik M, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD) (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
8. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-91
9. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978;200:21-7
10. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30
11. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6
12. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
13. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95
14. Houssa P, Dinensen B, Deberg M, et al. First direct assay for intact human proinsulin. Clin Chem 1998;44:1514-19
15. El Kenz H, Bergmann P. Evaluation of immunochemiluminometric assays for the measurement of insulin and C-peptide using the ADVIA Centaur. Clin Lab 2004;50:171-4
16. Holst JJ. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982;207:381-8
17. Takebayashi K, Suetsugu M, Wakabayashi S, et al. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007;92:2712-19
18. Korner A, Garten A, Bluher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783-91
19. MacDougald OA, Burant CF. The rapidly expanding family of adipokines. Cell Metab 2007;6:159-61
20. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23
21. Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-8
22. Fasching P, Ratheiser K, Nowotny P, et al. Insulin production following intravenous glucose, arginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 1994;43:385-9
23. Winer BJ. Statistical principles in experimental design. 2nd edition. McGraw-Hill; New York: 1971
24. Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:644-52
25. Williams-Herman D, Xu L, Teng R, et al. Effect of initial combination therapy with sitagliptin and metformin on beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2012;14:67-76
26. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62
27. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30
28. Hug C, Lodish HF. Medicine. Visfatin: a new adipokine. Science 2005;307:366-7
29. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-85
30. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-94
31. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 282:28175-88